NuVasive Specialized Orthopedics Surpasses 100 Peer-Reviewed Publications of the Precice System for Limb Lengthening | Business and finance


SAN DIEGO, April 26, 2022 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA) today announced a milestone of more than 100 peer-reviewed publications of the Precice® System (Precice) for conditions related to limb lengthening and reconstruction using NuVasive Specialty Orthopedics™ (NSO). The Precice System is an intramedullary nail that, once implanted, uses an external remote control (ERC) to lengthen the limb non-invasively.

“This milestone further reinforces the benefits Precice offers to orthopedic surgeons and their patients,” said Dr. Stuart Green, orthopedic surgeon at UC Irvine School of Medicine. “First introduced in 2011, Precice has been used successfully to overcome limb length deficiencies in thousands of patients worldwide with less pain and fewer complications than previously thought. demonstrate the important role the implant plays in modern limb reconstruction – helping to establish Precice as the standard of care today.”

Following the first publication in 2014 in Clinical orthopedics and related research,1 more than 100 peer-reviewed publications have been written in countries such as the United States, Germany and South Africa. Precice has been researched in dozens of journals, including The Journal of Bone and Joint Surgery, Journal of Orthopedic Trauma, Journal of the American Academy of Orthopedic Surgeons, and The Journal of Surgical Orthopedic Advances.

“With approximately 15,000 procedures in more than 45 countries, today’s announcement is another significant milestone for Precice,” said Pete Ligotti, chief executive of NSO. “We remain committed to bringing new technology to underserved markets to help achieve better outcomes for surgeons, and more importantly, patients.

NSO, a division of NuVasive, is focused on designing and innovating disruptive orthopedic solutions for complex orthopedic reconstruction and limb lengthening. Precice is used to treat long bone abnormalities resulting from congenital bone conditions, oncology or trauma. Proprietary technology includes a complex 60-piece internal gear system remotely activated and controlled by rare-earth permanent magnets. This advancement in limb lengthening allows for a precisely controlled distraction phase with the ability to customize treatment non-invasively to better meet individual patient needs.

Click here to learn more about the Precice system.

About NuVasive NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care and change lives. The company’s less invasive and procedurally integrated surgical solutions are designed to provide reproducible, clinically proven results. The Company’s comprehensive procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, surgical planning software, navigation and imaging solutions, adjustable implant systems magnetic spine and orthopedics, as well as intraoperative neuromonitoring technologies and services. With over $1 billion in net sales, NuVasive operates in more than 50 countries serving surgeons, hospitals and patients. For more information, please visit

Forward-Looking Statements NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if not materialized not or prove to be incorrect, could cause NuVasive’s results to differ materially from historical results or from those expressed or implied by such forward-looking statements. The potential risks and uncertainties that contribute to the uncertain nature of these statements include, among others, the risks associated with the acceptance of the Company’s surgical products and procedures by spine surgeons and hospitals, the development and acceptance of new products or product improvements, clinical and statistical verification of the benefits obtained from the use of NuVasive’s products, the Company’s ability to adequately manage inventory as it continues to introduce new products, its ability to recruit and retain management and key personnel; and other risks and uncertainties described in NuVasive’s press releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at NuVasive undertakes no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date on which it was made.

Show original content to download multimedia:

SOURCENuVasive, Inc.

Copyright © 2022 PR Newswire Association LLC. All rights reserved.


Comments are closed.